

# KRAS Inhibitor Industry Research Report 2025

<https://marketpublishers.com/r/K8A20F72AEFBEN.html>

Date: February 2025

Pages: 122

Price: US\$ 2,950.00 (Single User License)

ID: K8A20F72AEFBEN

## Abstracts

### Summary

According to APO Research, the global KRAS Inhibitor market was valued at US\$ million in 2024 and is anticipated to reach US\$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for KRAS Inhibitor is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for KRAS Inhibitor is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for KRAS Inhibitor is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of KRAS Inhibitor include Novartis, Jemincare, Amgen, Mirati Therapeutics, Innovent Biologics, Incyte, Erasca, Cardiff Oncology and BridgeBio Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

### Report Scope

This report aims to provide a comprehensive presentation of the global market for KRAS Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their

position in the current marketplace, and make informed business decisions regarding KRAS Inhibitor.

The report will help the KRAS Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The KRAS Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue (\$ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global KRAS Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

### Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

### KRAS Inhibitor Segment by Company

Novartis

Jemincare

Amgen

Mirati Therapeutics

Innovent Biologics

Incyte

Erasca

Cardiff Oncology

BridgeBio Pharma

Boehringer Ingelheim

#### KRAS Inhibitor Segment by Type

Lung Cancer

Colorectal Cancer

Pancreatic Cancer

Others

#### KRAS Inhibitor Segment by Application

Clinic Laboratories

Hospitals

Cancer Diagnostic Centres

Others

#### KRAS Inhibitor Segment by Region

North America

United States

Canada

Mexico

## Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

## Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Turkiye

GCC Countries

## Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS Inhibitor market,

and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KRAS Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of KRAS Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of KRAS Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

## Contents

### 1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

### 2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
  - 2.2.1 Global KRAS Inhibitor Market Size (2020-2031)
  - 2.2.2 Global KRAS Inhibitor Sales (2020-2031)
  - 2.2.3 Global KRAS Inhibitor Market Average Price (2020-2031)
- 2.3 KRAS Inhibitor by Type
  - 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US\$ Million)
  - 2.3.2 Lung Cancer
  - 2.3.3 Colorectal Cancer
  - 2.3.4 Pancreatic Cancer
  - 2.3.5 Others
- 2.4 KRAS Inhibitor by Application
  - 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
  - 2.4.2 Clinic Laboratories
  - 2.4.3 Hospitals
  - 2.4.4 Cancer Diagnostic Centres
  - 2.4.5 Others

### 3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS

- 3.1 Global KRAS Inhibitor Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global KRAS Inhibitor Sales (K Units) of Manufacturers (2020-2025)
- 3.3 Global KRAS Inhibitor Revenue of Manufacturers (2020-2025)
- 3.4 Global KRAS Inhibitor Average Price by Manufacturers (2020-2025)

- 3.5 Global KRAS Inhibitor Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of KRAS Inhibitor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of KRAS Inhibitor, Product Type & Application
- 3.8 Global Manufacturers of KRAS Inhibitor, Established Date
- 3.9 Global KRAS Inhibitor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

## **4 MANUFACTURERS PROFILED**

### 4.1 Novartis

- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Novartis KRAS Inhibitor Product Portfolio
- 4.1.5 Novartis Recent Developments

### 4.2 Jemincare

- 4.2.1 Jemincare Company Information
- 4.2.2 Jemincare Business Overview
- 4.2.3 Jemincare KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Jemincare KRAS Inhibitor Product Portfolio
- 4.2.5 Jemincare Recent Developments

### 4.3 Amgen

- 4.3.1 Amgen Company Information
- 4.3.2 Amgen Business Overview
- 4.3.3 Amgen KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Amgen KRAS Inhibitor Product Portfolio
- 4.3.5 Amgen Recent Developments

### 4.4 Mirati Therapeutics

- 4.4.1 Mirati Therapeutics Company Information
- 4.4.2 Mirati Therapeutics Business Overview
- 4.4.3 Mirati Therapeutics KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Mirati Therapeutics KRAS Inhibitor Product Portfolio
- 4.4.5 Mirati Therapeutics Recent Developments

### 4.5 Innovent Biologics

- 4.5.1 Innovent Biologics Company Information
- 4.5.2 Innovent Biologics Business Overview
- 4.5.3 Innovent Biologics KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)

- 4.5.4 Innovent Biologics KRAS Inhibitor Product Portfolio
- 4.5.5 Innovent Biologics Recent Developments
- 4.6 Incyte
  - 4.6.1 Incyte Company Information
  - 4.6.2 Incyte Business Overview
  - 4.6.3 Incyte KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
  - 4.6.4 Incyte KRAS Inhibitor Product Portfolio
  - 4.6.5 Incyte Recent Developments
- 4.7 Erasca
  - 4.7.1 Erasca Company Information
  - 4.7.2 Erasca Business Overview
  - 4.7.3 Erasca KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
  - 4.7.4 Erasca KRAS Inhibitor Product Portfolio
  - 4.7.5 Erasca Recent Developments
- 4.8 Cardiff Oncology
  - 4.8.1 Cardiff Oncology Company Information
  - 4.8.2 Cardiff Oncology Business Overview
  - 4.8.3 Cardiff Oncology KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
  - 4.8.4 Cardiff Oncology KRAS Inhibitor Product Portfolio
  - 4.8.5 Cardiff Oncology Recent Developments
- 4.9 BridgeBio Pharma
  - 4.9.1 BridgeBio Pharma Company Information
  - 4.9.2 BridgeBio Pharma Business Overview
  - 4.9.3 BridgeBio Pharma KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
  - 4.9.4 BridgeBio Pharma KRAS Inhibitor Product Portfolio
  - 4.9.5 BridgeBio Pharma Recent Developments
- 4.10 Boehringer Ingelheim
  - 4.10.1 Boehringer Ingelheim Company Information
  - 4.10.2 Boehringer Ingelheim Business Overview
  - 4.10.3 Boehringer Ingelheim KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
  - 4.10.4 Boehringer Ingelheim KRAS Inhibitor Product Portfolio
  - 4.10.5 Boehringer Ingelheim Recent Developments

## **5 GLOBAL KRAS INHIBITOR MARKET SCENARIO BY REGION**

- 5.1 Global KRAS Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global KRAS Inhibitor Sales by Region: 2020-2031

- 5.2.1 Global KRAS Inhibitor Sales by Region: 2020-2025
- 5.2.2 Global KRAS Inhibitor Sales by Region: 2026-2031
- 5.3 Global KRAS Inhibitor Revenue by Region: 2020-2031
  - 5.3.1 Global KRAS Inhibitor Revenue by Region: 2020-2025
  - 5.3.2 Global KRAS Inhibitor Revenue by Region: 2026-2031
- 5.4 North America KRAS Inhibitor Market Facts & Figures by Country
  - 5.4.1 North America KRAS Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
  - 5.4.2 North America KRAS Inhibitor Sales by Country (2020-2031)
  - 5.4.3 North America KRAS Inhibitor Revenue by Country (2020-2031)
  - 5.4.4 United States
  - 5.4.5 Canada
  - 5.4.6 Mexico
- 5.5 Europe KRAS Inhibitor Market Facts & Figures by Country
  - 5.5.1 Europe KRAS Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
  - 5.5.2 Europe KRAS Inhibitor Sales by Country (2020-2031)
  - 5.5.3 Europe KRAS Inhibitor Revenue by Country (2020-2031)
  - 5.5.4 Germany
  - 5.5.5 France
  - 5.5.6 U.K.
  - 5.5.7 Italy
  - 5.5.8 Russia
  - 5.5.9 Spain
  - 5.5.10 Netherlands
  - 5.5.11 Switzerland
  - 5.5.12 Sweden
  - 5.5.13 Poland
- 5.6 Asia Pacific KRAS Inhibitor Market Facts & Figures by Country
  - 5.6.1 Asia Pacific KRAS Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
  - 5.6.2 Asia Pacific KRAS Inhibitor Sales by Country (2020-2031)
  - 5.6.3 Asia Pacific KRAS Inhibitor Revenue by Country (2020-2031)
  - 5.6.4 China
  - 5.6.5 Japan
  - 5.6.6 South Korea
  - 5.6.7 India
  - 5.6.8 Australia
  - 5.6.9 Taiwan
  - 5.6.10 Southeast Asia
- 5.7 South America KRAS Inhibitor Market Facts & Figures by Country
  - 5.7.1 South America KRAS Inhibitor Market Size by Country: 2020 VS 2024 VS 2031

5.7.2 South America KRAS Inhibitor Sales by Country (2020-2031)

5.7.3 South America KRAS Inhibitor Revenue by Country (2020-2031)

5.7.4 Brazil

5.7.5 Argentina

5.7.6 Chile

5.8 Middle East and Africa KRAS Inhibitor Market Facts & Figures by Country

5.8.1 Middle East and Africa KRAS Inhibitor Market Size by Country: 2020 VS 2024 VS 2031

5.8.2 Middle East and Africa KRAS Inhibitor Sales by Country (2020-2031)

5.8.3 Middle East and Africa KRAS Inhibitor Revenue by Country (2020-2031)

5.8.4 Egypt

5.8.5 South Africa

5.8.6 Israel

5.8.7 Turkey

5.8.8 GCC Countries

## **6 SEGMENT BY TYPE**

6.1 Global KRAS Inhibitor Sales by Type (2020-2031)

6.1.1 Global KRAS Inhibitor Sales by Type (2020-2031) & (K Units)

6.1.2 Global KRAS Inhibitor Sales Market Share by Type (2020-2031)

6.2 Global KRAS Inhibitor Revenue by Type (2020-2031)

6.2.1 Global KRAS Inhibitor Sales by Type (2020-2031) & (US\$ Million)

6.2.2 Global KRAS Inhibitor Revenue Market Share by Type (2020-2031)

6.3 Global KRAS Inhibitor Price by Type (2020-2031)

## **7 SEGMENT BY APPLICATION**

7.1 Global KRAS Inhibitor Sales by Application (2020-2031)

7.1.1 Global KRAS Inhibitor Sales by Application (2020-2031) & (K Units)

7.1.2 Global KRAS Inhibitor Sales Market Share by Application (2020-2031)

7.2 Global KRAS Inhibitor Revenue by Application (2020-2031)

7.2.1 Global KRAS Inhibitor Sales by Application (2020-2031) & (US\$ Million)

7.2.2 Global KRAS Inhibitor Revenue Market Share by Application (2020-2031)

7.3 Global KRAS Inhibitor Price by Application (2020-2031)

## **8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET**

8.1 KRAS Inhibitor Value Chain Analysis

- 8.1.1 KRAS Inhibitor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 KRAS Inhibitor Production Mode & Process
- 8.2 KRAS Inhibitor Sales Channels Analysis
  - 8.2.1 Direct Comparison with Distribution Share
  - 8.2.2 KRAS Inhibitor Distributors
  - 8.2.3 KRAS Inhibitor Customers

## **9 GLOBAL KRAS INHIBITOR ANALYZING MARKET DYNAMICS**

- 9.1 KRAS Inhibitor Industry Trends
- 9.2 KRAS Inhibitor Industry Drivers
- 9.3 KRAS Inhibitor Industry Opportunities and Challenges
- 9.4 KRAS Inhibitor Industry Restraints

## **10 REPORT CONCLUSION**

## **11 DISCLAIMER**

## I would like to order

Product name: KRAS Inhibitor Industry Research Report 2025

Product link: <https://marketpublishers.com/r/K8A20F72AEFBEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K8A20F72AEFBEN.html>